The layoffs will affect employees in research, clinical development and administrative roles.
In addition, Dynavac CEO Eddie Gray will step down from his role Aug. 1 as part of the restructuring effort.
The plan comes as the biotech works to shift its focus and resources from immuno-oncology and to vaccines, including its first commercial product, which is a hepatitis B vaccine.
Read the full report here.
More articles on pharmacy:
How hospitals can better align the pharmacy to achieve its strategic goals
Google sister-company Verily partners with big pharma for clinical trials
Merck’s Keytruda fails late-stage trial as standalone treatment for breast cancer
